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A B S T R A C T
Recent sociological research has raised important sociological and ethical questions about the role of financial
rewards in terms of healthy volunteer involvement in clinical trials. Research suggests that it would be parochial
to assume financial rewards alone are sufficient to explain repeat healthy volunteering. This paper explores other
factors that might explain repeat healthy volunteering behaviours in phase I clinical drug trials. Drawing on
qualitative research with healthy volunteers, the paper argues that while healthy volunteers make rational
decisions to take part in drug trials, understanding how they become repeat volunteers requires considering
varied relationships and networks involved. Drawing on Deleuze's concept of ‘event’ and ‘becoming-with’, the
paper illustrates the relational, processual and embodied nature of trust in repeat healthy volunteer involvement
in clinical drug trials. The paper concludes that repeat healthy volunteering is a constant flux of negotiating trust
and mistrust. The paper contributes to sociological debates about trust and public engagement with technolo-
gical innovations to illustrate trust among healthy volunteers as processual and changeable.
1. Introduction
Clinical drug trials are globally established as the standard for en-
suring safety and efficacy before marketing medical drugs. The proce-
dure involves complex and elaborate processes (Rajan 2006). Pre-clin-
ical phase, tests for iterative toxicity and drug safety data collection,
often involves animal testing followed by a further four phases in hu-
mans. Phase I - the focus of this paper - involves testing investigational
medicinal products (IMP) on a limited number of healthy volunteers to
ascertain safety and determine minimum and maximum dosages to be
administered with no health benefit from participation. IMPs can in-
volve drugs already on the market being reconsidered to treat other
conditions. In Phase II, the drug is tested on more substantial numbers
to determine further efficacy and optimal dosages. Participants again
experience no discernible benefit. Phase III involves several thousand
patients with the condition for which the drug is developed; IMP is
tested for safety, efficacy, and therapeutic potential. The fourth phase,
is post-marketing surveillance, comparing the IMP's effectiveness in a
wide range of patients with the same condition (see Petryna, 2009;
Pocock, 2013).
With heightened public demands for novel treatments (Petryna,
2009), clinical drug trials are increasingly taking place across the UK,
requiring more participants. Between 2005 and 2016, the Medicines
and Healthcare Regulatory Authority (MHRA) reviewed approximately
11,473 Clinical trials applications. Of these, 2702 were for phase I
clinical trials (MHRA, 2018). For these trials specifically, participation
has been attractive not only to those involved in the drug development
processes, such as Contract Research Organisations (CROs) (Shuchman,
2007) but to healthy participants. Recent sociological research has
shown how for some healthy volunteers participation is a means for
earning or supplementing income (Abadie, 2010; Fisher and Kalbaugh,
2011; Mwale, 2017; Walker et al., 2018). Alluring rewards have led
some to participate in multiple drug trials simultaneously. This ten-
dency risks the study's integrity; participants' blood may contain rem-
nants of drugs from one trial that interact with the experimental drug in
another, compromising outcomes and posing a risk to the participant's
health (Abadie, 2010). However, healthy volunteers still participate,
some deceiving research teams by not declaring histories of involve-
ment (Dresser, 2013; Monahan and Fisher, 2015). This poses several
challenges for clinical drug trials: Companies are concerned about re-
putation if unexpected adverse effects occur, compromising the meth-
odological integrity of the trial, and risks to the safety and wellbeing of
the participants. Concerns about healthy volunteer safety and public
perceptions mean repeat-volunteering attracts professional and policy
attention. Research Ethics Committees and similar structures are con-
sidered spaces for ensuring continued public trust in clinical research
(Hedgecoe, 2014; Hudson et al., 2016). However, these alone are in-
sufficient in explaining how public trust is developed and maintained in
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clinical drug trials.
Consequently, repeat healthy volunteering, the tendency of healthy
volunteers to frequently enroll in clinical drug trials without leaving
enough trial drug wash out period, has taken political and policy centre
stage, particularly in the face of recent tragedies. In 2016 in France, one
participant died and several dozen were admitted to hospital after
suffering severe unexpected side effects. Ten years prior in London, six
healthy volunteers suffered life-changing cytokine release syndrome
with multi-organ failure after being infused with a monoclonal anti-
body in a clinical trial (Hedgecoe, 2013; Mwale, 2016; Abadie et al.,
2019). Such events have raised public disquiet about safety, however,
increasing numbers of people repeat volunteer, sometimes indis-
criminately (Hale, 2007; Abadie, 2010; Monahan and Fisher, 2015).
Concerns have led to increased regulatory measures such as The Over-
volunteering Prevention Strategy (TOPS) installed to facilitate tracking
and curb indiscriminate repeat volunteering (Allen et al., 2017). Its
effectiveness is highly contested in the CRO community (Berelowitz and
Taubel, 2013) and this debate is beyond the scope of this paper.
However, the installation of this measure signals the significance of the
challenges repeat volunteering poses to the business of clinical drug
trials.
This paper explores how participants rationalise repeated involve-
ment in clinical drug trials and negotiate and manage questions of trust
when health and safety cannot be guaranteed. While financial in-
centives are usually the central motivating factor, repeat volunteering is
based on a set of relationships and experiences within the process that
facilitate the development of trust. Healthy volunteers draw on inter-
actions with professionals, social networks and bodily experiences to
become repeat volunteers. Research has focused on the need for im-
provement in institutional practices such as information provision and
informed consent. However, there is little attention to individual con-
siderations when engaging with institutions or practices within and
outside these processes. Drawing on interview data with 35 healthy
volunteers in the UK and using concepts of ‘becoming-with’ and ‘event’
the paper shows how networks and relationships bring about a constant
negotiation of trust and mistrust. I argue that trust is crucial to the
practice of repeat healthy volunteering and is mediated by both rela-
tions and institutionalised process of consent in the clinical drug trial
process.
2. Trust and human entanglement with medical practices
Following watershed incidents such as the Nuremberg (Marks,
2006) and Tuskegee (Brandt, 1978) experiments, trust has been at the
centre of policy and public debates about medical research for decades.
Debates centre on the need for building trust between patients and
medical professionals (Calnan and Rowe, 2007; Brown et al., 2011) and
transparency to ensure continued public involvement in medical re-
search (Mechanic, 1996). Trust in these settings is concerned with en-
suring patients make informed decisions, including avoiding the pos-
sibility of therapeutic misconceptions (Appelbaum et al., 1987)
whereby patients, as participants in medical research, should be ex-
plicitly informed about the non-therapeutic nature of clinical trials.
Questions of trust in medicine and medical research remain of concern.
Where trust in clinical drug trials concerning healthy volunteers is
discussed, this focusses on implications for trust in research processes in
the aftermath of unexpected adverse incidents. Concerns relate to in-
stitutional practices and how these could be improved to retain public
trust (O'Neill, 2002; Hedgecoe, 2013). In the US, ethnicity shapes public
attitudes to biomedical research; African Americans are thought to be
the least trustful of biomedical research due to the historical abuse of
minority groups illustrated by the infamous Tuskegee experiment
among others (Corbie-Smith et al., 2002; Brown and Topcu, 2003; Katz
et al., 2003; Bates and Harris, 2004; Wendler et al., 2005 Durant et al.,
2011). For those participating in uncertain research, whose outcomes or
effects cannot be assured, they might require to draw on ‘readily
available resources such as relationships, feelings and intuition’
(Alaszewski and Coxon, 2009; 201), to establish and sustain trust or
distrust.
Elliott (2008) found that healthy volunteers shared information
when felt they were not treated respectfully; this information was as-
tutely used by others in decision-making to avoid enrolling in Clinical
Trials Units (CTU) with poor records of care, illustrating how trust is
about social relations between volunteers and CTUs. Significantly in
Elliott (2008) participants did not focus on experiences of unexpected
adverse effects but on the quality of interpersonal relationships and
facilities. They also reported on the quality of care such as poor blood
taking skills (Elliott, 2008). Reference to professional skills is essential,
highlighting the embodied nature of clinical trials and personal sense of
safety and trust in the team's abilities. It appears that repeat partici-
pation is contingent on participants' perceived positive experiences and
relationships. Elliott (2008) concludes that unless participants feel they
have no choice, they will not go back to a facility where they had ne-
gative experiences. Trust is embedded in a complex set of collective
relations and as an individual, social and institutional process involving
both relational and cognitive processes.
3. Repeat volunteering as rational action: ensuring trust in
clinical trials
Current approaches to public involvement in medical research can
be traced to the Helsinki declaration. This signifies a key moment in the
history of clinical trials, highlighting the impact of abuse and need for
humans rights in medical research (GAWMA, 2014). Whilst there have
been numerous failings (Hedgecoe, 2017), a thrust of the declaration
was the need to end paternalistic practices in clinical trials, encourage
agency and restore public trust by ensuring voluntary involvement and
informed consent. Today, these processes are established emblems of
good research and a basis for public trust. Influenced by classical eco-
nomic assumptions of individuals as rational actors (Becker, 1963),
participants in clinical drug trials are construed as capable of making
rational decisions, weighing benefits and risks. Trust is addressed by
providing information and ensuring transparency. Risk is seen as an
objective issue resolved by research ethics committees who weigh po-
tential risks posed by the trial drug against the broader benefits. This
approach is imbued with Bentham’s (1996) classic utilitarian ideal of
the greatest utility for the greatest number, tying into ideas of non-
maleficence and beneficence (Beauchamp, 2008), cornerstones of
ethical medical practice. Public trust in health professionals is pre-
dicated on their moral obligation to do good while the public needs to
participate in research for the benefit of the greater good. Underpinning
this approach are notions of rational and capable subjects.
Social science research into trust in medical settings has mostly
taken psychological (Glaeser et al., 2000) and political science (Blais
and ST-Vincent, 2011) approaches, trust understood through the lens of
individual liberty and rational choice. This archetypal perception of
human actors is in keeping with what Giddens (1991) terms a rational
self in reflexive modernity, evident in bioethical principles' emphasis on
individuals and their liberties. Information provision is seen as the basis
on which trust is developed and maintained, as individuals make in-
formed decisions through access to information. The limitation of this
view is that it presents a universal model of the rational individual
which negates the complex multifaceted nature of social realities of
trust (Lewis, 1985). Corrigan (2003) challenged these assumptions,
arguing that overemphasis on the fully informed rational individual
divorces the consent process from its social context and negates the role
of social networks in everyday medical encounters, risk perception and
decision-making. O'Neill (2003); Hedgecoe (2004); Dixon-Woods et al.
(2007) and Felt et al. (2009) indicate limitations of information pro-
vision in resolving all ethical questions in medical research; instead
they call for an approach to informed consent that takes complexities
into account.
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While medical literature (de Balicourt and Dobsworth, 2013; Kahan
et al., 2016) presents trust as an objective issue resolved by transpar-
ency, a sociological perspective considers how understandings of trust
are produced, embedded and contoured by a complex set of social re-
lations and processes (Brown and Gale, 2018) imbued with competing,
contradictory power relations and demands (Braidotti, 2013; Dennis,
2017). Understanding trust in clinical drug trials requires going beyond
information provision to include relational and processual elements as
recent work on drug use has shown. Keane (2003) and Dennis (2016,
2017) question approaches to substance misuse focussing on rights and
abilities. They argue it reduces complexities to anthropocentric ex-
perience removed from the multiple parties and processes involved.
Though a different issue, there are parallels between injecting drug use
and healthy volunteering; both pose risks to individual health with
uncertain outcomes. Rather than focussing on rationality and individual
rights, shifting the analytical gaze to broader contexts and relations
enables prospects for understanding nuances of trusting among repeat
volunteers, regardless of what study protocols may suggest. To a sig-
nificant extent, involvement in clinical trials is at one's own risk. Par-
ticipants put their trust in the abilities and intentions of administering
professionals. Understanding how participants rationalise perceived
risks and decisions to act as repeat volunteers requires utilising an
approach to trust that considers the diverse networks and assemblages
in which healthy volunteering takes place.
4. Theoretical framework
In this paper trust is explored as a relational, processual and em-
bodied formation requiring constant negotiation and management. To
better understand how healthy volunteers develop trust to become re-
peat volunteers, I draw on Deleuze's concept of the ‘event’ and ‘be-
coming’ to illustrate the embodied and connected nature of trust. As
Law (2009) and Latour (2005) argue, a relational approach to bodies
shows that actors are not inherently rational and capable of agency.
Instead, individual action emanate from specific associations of net-
works that ‘spatially and temporarily link one actor with another’ (Duff,
2014). Therefore, an act of individual agency to trust or not to trust
should be understood as entanglement with multiple bodies. This is not
to suggest that all actors have the same experiences, as actors' capacities
differ depending on the nature of the encounters and relations they
have in the clinical trial process. In a Deleuzian sense, individual bodies
act as “conduits” through which individual agency is produced, dis-
tributed and used (Armstrong, 1997). Trust is not a single-moment issue
but processual, embedded in networked relations with humans and
non-humans. For Deleuze, relations are about how the body and its
encounters ‘become’ composed with the affects of other bodies; in-
dividual subjectivity should not be seen as isolated but embedded in a
situated assemblage of diverse connections. Relations, therefore, are
about embodied subjectivity situated in multiple relations with affect at
the core, bringing bodies together in subjective experiences and en-
counters with the affect of other bodies (Duff, 2014; Dennis, 2017).
For Deleuze, the event signifies the transformation of bodies and
subjects in the specific relations in which they are involved; ‘becoming’
and ‘events’ are ontologically prior to being, thus subjectivity and ex-
periences are processual rather than fixed. Applying this view to
healthy volunteer involvement in clinical trials, the clinical trial as
‘event’ involves the specific status of observable affairs ‘in the comingling
of bodies within and outside [the clinical drug trial units], and the in-
corporeal transformation rendered in such bodies by the event’ of the
clinical trials with its related activities and processes (Duff, 2014; 46;
Marks, 1998). Becoming pertains to those moments in which in-
dividuality comes into being, requiring an approach ‘underpinned by a
relational and processual ontology, with the human always caught in the
ebbs and flows of becoming’ (Dennis, 2017; 340). Fraser (2011) analysis
of the ‘event’ in STS and Deleuzean philosophy identifies two versions,
one where the event is defined as ‘being with’, where the components of
the event ‘co-habit’ as the event proceeds, interacting with, and re-
maining unchanged in relation to one another. The other event is
characterised as a ‘becoming-with’ as the components mutually change,
or intra-act (Michael, 2015; Dennis, 2017). This paper draws on the
latter.
I draw on Duff, 2012, 2016; Dilkes-Frayne (2014); Race (2015) and
Dennis (2017) on injecting drug use; they apply the concept of the
‘event’ and ‘becoming-with’ to understanding injecting drug use, con-
tending that attention should be shifted from ‘who acts’ to ‘what oc-
curs’. Here, drawing on Deleuze brings into focus a different question –
‘what becoming-with’ occurs in the clinical drug trial as an ‘event’. As
Dennis (2017; 340) posits, ‘The hyphen in ‘becoming-with drugs' is vital as
it highlights that there are no pre-defined bodies – ‘the body’ or ‘drug’ – but
these come to ‘matter’ (in its dual sense) in relation to each other’. Parallels
can be drawn with clinical drug trials as healthy volunteering occurs in
a complex set of relations involving technology, drugs, institutional
processes and individual bodies coming together in the trial, shaping
and influencing each other. ‘Becoming-with’ refers to a continuous state
that is not pre-defined or bounded but in constant flux. In Dennis’
(2017) reading of Stagoll (2010), ‘the event is not a disruption of some
continuous state, but rather the state is constituted by events “underlying” it
that when actualised, mark every moment of the state as a transformation’
(2010: 90). Central here is acknowledgement of the relational nature of
encounters in the event and how they shape each other. Therefore,
what may be understood as individual informed action is a product of
multiple continuous relations.
5. Method
This qualitative research study aimed to investigate ethical and
regulation dimensions of healthy volunteer involvement in the UK. The
study involved semi-structured interviews (Kvale, 1983; Mwale, 2014)
with 35 healthy volunteer participants in clinical drug trials. Semi-
structured interviews obtained in-depth understandings of the motiva-
tions and experiences of healthy volunteers in commercial phase I
clinical drug trials. Participants were resident in Belfast, Edinburgh,
London, Leeds Liverpool and Manchester.
A survey questionnaire was used as a recruitment tool. Respondents
were invited to give contact details to take part in interviews. Of 189
respondents 50.3% (95) expressed willingness to participate in inter-
views and 13.2% (25) of the 95 were interviewed. The 25 were re-
cruited on the basis that they were looking to participate or had par-
ticipated in one or more clinical drug trials. A further 10 participants
were recruited via snowballing. All but one participant were in em-
ployment at the time of interview. Participants whose data are used in
this paper had participated in at least one clinical drug trial.
Experiences of clinical trial involvement ranged from one to ten or
more.
Interviews were face-to-face apart from two telephone and two
skype interviews for participants who were unavailable for face-to-face
meetings. Interviews took place at participants' convenience and were
conducted in public spaces such as cafés, parks or similar places for
comfort (Mwale, 2014) lasting on average 60 min. Interviews explored
motivation, views of monetary rewards, risks, their interaction with
research, experiences of adverse effects, and how their involvement in
clinical trials shaped perceptions of their bodies. Interview length
ranged from 25 to 90 min, with the majority lasting over an hour.
Interviews were recorded and transcribed verbatim. Data were
analysed using a thematic analysis approach (Braun and Clarke, 2006).
This approach involves a six-step process involving familiarisation and
immersion in the data by reading and re-reading to enable intimate
understanding of the material. A search for themes follows before
coding the data, identifying characteristics to enable answering the
research questions being explored. Codes are further analysed and re-
fined and finally, themes and data extracts are woven into a narrative in
relation to the literature. This provides flexibility in that while
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questions direct data analysis, it allows for new ideas and themes to
emerge. Combining thematic analysis and a Deleuzean approach en-
abled going beyond the ‘individual’ to consider relational aspects of
bodies. Participants were fully informed and assured of their rights to
withdraw or not to answer any questions they found uncomfortable.
Identities of all participants and organisations involved are anon-
ymised. Ethics approval was obtained from the University of Sussexs
Arts and Social Science ethics review committee.
6. The toss-up: fragile trust as a point of departure
If they have not tested the drug on anyone? …. While I think it is
important … that drugs are tested thoroughly before they are made
available to the wider public, I think there is a toss-up in selling your
health and whether your health is ever worth any amount of fi-
nancial compensation that you may get from taking part in the trial,
because you can never be 100% sure … [of the outcome of the drug
trial] (Shivaune)
Shivaune's account demonstrates a common issue healthy volun-
teers contend with during the early stages and for some throughout
their involvement in clinical drug trials. Healthy volunteers become
involved while remaining sceptical about the processes. Shivaune uses
the ‘toss-up’ analogy to highlight uncertain outcomes, potential risks to
the participant's health and sufficiency of the financial rewards on offer.
The participant's description demonstrates awareness of the risks in-
volved, albeit based on incomplete knowledge as researchers do not
know yet the effects of the drug, hence the purpose of conducting trials.
This feeling of mistrust was not only about the experimental drugs but
extended to healthcare professionals themselves:
For me the most concern was even if I trusted the guys [profes-
sionals administering the trial], how can I know this is the drug they
describe on paper and the effects they say it has? What if they write
one thing on paper and give me another drug?… In the end, I had to
convince myself that it is not possible, but even then, I struggle with
that question every time I go into a clinical trial … (Marko).
This illustrates that although providing information to participants
is useful in aiding the consent process, analysis should go beyond
normative consent procedures to consider the diverse human relations
in which trust develops. Marko suggests that professionals may lie to
him, illustrating tensions between trust and not-trusting, and how this
is mediated by broader concerns. Information provided was subject to
the same mistrust as the clinical trial process itself. However, it should
be highlighted that despite these reservations Marko, at the time of the
interview, had taken part in more than ten clinical drug trials.
For others, mistrust is underpinned by views and comments of wider
networks such as family and friends who may see involvement in
clinical trials as a risky endeavour. For Elliot, this was significant in his
decision to participate in the first trial.
My mum said, “Don't be stupid, it's a silly idea. It's reckless. You will
make yourself ill and there is no need for you to do that”. I tried
explaining that it was safe … in a way there was an undertone that I
should do something productive with my time [rather] than getting
myself involved in clinical trials. “Get a job or something” (Elliot).
Yeah, I told them [the family] once. They were a little bit afraid for
me; they did not have a lot of the facts. I think they just heard it's a
trial and they were scared. My dad asked me to go back home if I
was having problems with money. He will look after me, he said …
[Hank].
Despite policy attempts to improve public perceptions of clinical
trials, public mistrust remains. Questions of trust or mistrust are equally
shaped by social networks and proximity of risk. In the above account,
the immediate family seemingly aids mistrust even when the partici-
pants had managed their concerns about the clinical drug trial. Elliot
did not take part in any further trials as his family could not accept his
decision to be a healthy volunteer. For Hank, family views meant that
he always took time to research drugs to be trialled so he could explain
this and ease their reservations. However, Hank also positions his fa-
mily as not knowledgeable enough in justifying his decision to parti-
cipate. Therefore, attention should be paid to affect and how decisions
to proceed against family advice often brought feelings of guilt while
simultaneously family's deficit in clinical trial knowledge can be used to
justify decisions. Trust should be viewed beyond making sense of expert
information provided in participant information sheets as in negotia-
tion with wider social, family, expectations. Trust among healthy vo-
lunteers shifts from being perceived as an issue resolved by routinised
and taken-for-granted practice of information provision to a complex
social event. Though information provision is essential, broader social
networks enable interpretation and validation of decisions.
For other participants, trust as an assemblage is illustrated in an
awareness of connections between the drug trial process, humans and
non-humans, who are used in this process as human substitutes.
Initially, I thought, “I can't do these because the risk is too high”. I
know it may have been tested say, on animals like rats [and]
monkeys or whatever but the human body is different … You know,
everybody has different enzymes and every species has different
ways of dealing with drugs, so what may happen in a dog may be
different to what may happen in humans, can't be replicated in
humans (Jamie).
Therefore, trust in the trial manifests beyond human roles. Jamie
questions the role of non-human actors as an information source and
confirmation of the safety of clinical drug trials. This moves the
common conception of healthy volunteering as a bounded event based
on scientific facts to a fluid process in which participants consider
multiple, competing and contradictory sources of information to ne-
gotiate questions of trust. After Deleuze (2004), trust in clinical drug
trials involves negotiating the constant vacillation between trusting and
not-trusting, management of uncertainties of outcomes and social per-
ceptions of acceptable risk-taking. Therefore, trust is not just born out
of an objective scientific process but understood best when located in
an array of social relations, human and non-human, including tech-
nology:
When I started I was like “I don't want to be a complete guinea pig”
the animals can be, so I googled about the drug content and the
institution. So, I started with drug trials of drugs already in use, but
with time I have found myself doing more very first phase drug trials
… (Cullum)
The first trial … I had already done all the research online [note the
role of information technologies] and a friend is a chemical en-
gineer, so I knew there wasn't anything really to worry about in
terms of anything going wrong. … I could have trusted them and
just took their word for it like that. I was not sure [I could] (Lauren)
This indicates tensions between scientific facts and tacit knowledge.
Participants expressed caution when embarking on participation in
clinical trials. Concerns about inherent risks led others to take evasive
steps including participating in what they deemed low-risk studies,
often trials of drugs already on the market. For some, this involved
conducting further research via social networks or ICT sources to es-
tablish the safety of the experimental drug. As Jarret (2015) and King-
O’R’iain (2014) state, ICT technologies should be seen as relational
artefacts to which and through which relations with self and others are
mediated and established. Participants used ICTs not only for in-
formation (Miller, 2008) but as spaces for verifying and relating to self
when making decisions that are seen as private, regardless of perceived
inaccuracies. More than cognition and interpretation of a participant
information sheet, affect and social relations shape decision-making
processes. The internet is a site of more than ‘disembodied rationality’,
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rather it is a space ‘for physical arousal, heightened emotion and the cul-
tivation and maintenance of rich social relationships’ (Jarret, 2015; 121).
Using ICTs, social networks and attendant affects, participants create
their own knowledge practices (Orlikowski, 2002) as a basis for their
trust.
Becoming trusting then involves considerable uncertainty and dis-
order rather than routinised consent processes. As Corrigan (2003:787)
observes ‘arguments that focus on informed consent as an absolute moral
principle result in a reductionist abstraction and empty ethics that strips the
principle of consent away from its social context’. Understanding repeat
involvement in clinical drug trials requires considering the role of in-
formation provision and social contexts with the constant management
and negotiation of risk perception on the one hand while on the other
managing and justifying one's healthy volunteer status. Therefore,
trusting becomes an assemblage of intricately bounded processes in
which technology, non-human actors and human relations interact to
bring about the act of participation.
Healthy volunteering becomes an involved process, disrupting the
borders of real facts (scientific) and knowing (subjective epistemolo-
gies) (Corrigan, 2003; Dennis, 2017). Reference to ‘the first trial’ or ‘the
start’ suggests that for these participants, trusting or not-trusting shifts
over time. In terms of ‘becoming-with’, trust does not develop solely
from a fixed set of relations such as information provision but includes
wider social relations. Trust takes diverse meanings at different times,
shaped by relationships in these encounters.
7. ‘Becoming-with’ a ‘seasoned’ repeat healthy volunteer
Trust among healthy volunteers should not be seen as an objective
process with a capable calculative rational individual, willing to take
risks. Rather I suggest an awareness of the complex, fluid nature of trust
involving negotiation of a complex set of relations and interests. Here, I
appropriate Dennis’ (2017) reading of Deleuze's idea of ‘becoming-with’
to refer to the fragility and contingency of trust among healthy volun-
teers. ‘Becoming-with’ a healthy volunteer is a complex process; in
addition to making sense of varied information, it requires willingness
to manage corporeal discomforts and dehumanising experiences:
… to them we were just numbers on hospital beds and not people.
It's quite strange, not that it was obvious, but in subtle ways. But you
know, it (being on the trial) does really feel that you are just a
specimen on trial (Shivaune).
… once you enrol, you become just a number; you are just there, you
are not you. So it can be quite hard to deal with sometimes, and the
powerlessness as well… because basically to them you are just data,
you know, but have value in the form of data and the money it
represents, not the human being I am … (Jake)
This illustrates a familiar feeling among these participants, de-
monstrating that to become a volunteer, one has to be willing to be seen
as an item in the clinical drug trial process. For most participants, the
first lesson on their healthy volunteer journeys was an acknowl-
edgement that the body has become a mere object in the process.
Becoming-with a healthy volunteer involves being able to manage the
tensions between being yourself and being ‘othered’ (Jensen, 2011).
The idea of being othered can be a shock to those just starting on their
clinical trial journey, as illustrated by Dominique's experience: ‘ … to
start with its the change in the treatment when you are on the ward for the
trial. It can be a shock … when suddenly staff who were friendly start to
refer to you as a number..’ This also illustrates that becoming-with a
healthy volunteer inadvertently requires managing complex power re-
lations. To repeatedly participate, one has to undergo a transforma-
tional process of managing the consequences of being treated as the
other. The Clinical Trials Unit as a space for surveillance and control
becomes apparent as participants have to abide by set rules, including
eating, sleep times and what items one is allowed to bring in: ‘I couldn't
have my make up on or walk outside-you are confined in this space’ (Shi-
vaune).
It requires developing the ability to withstand the inconveniences of
needle pricks, interrupted sleep and unexpected adverse drug effects. As
Jon suggests: ‘doing this [clinical drug trials] as often as I have you become
seasoned or more experienced if you like, able to cope [with the challenges
posed by the trial]. This identifies the role of external factors alongside
the experience of managing affect and the corporeal experiences of
adverse drug effects. It is learning to cope with these factors that fa-
cilitates becoming ‘seasoned’ and experienced as illustrated by Mia: ‘ …
you cannot do this if you want comfort, you register to know this will be
uncomfortable … ' or as another participant elaborates, describing a
fellow participant who was not coping with the pressures, ‘ … She was
always bitchin … and complaining about everything from 6 to 6. We had a
few words … because you see, if someone decides to come on a trial, you
must be ready for what it brings’ (Jules).
For Jules ‘becoming-with’ a ‘seasoned’ volunteer requires an ability
to manage feelings and endure associated inconveniences and dis-
comforts. Not reacting to discomforts and managing affect become
markers of a ‘seasoned’ healthy volunteer, indicating a transformation
from inexperienced to experienced healthy volunteer. However, there is
a contradiction in Jules account; while complaining is disallowed,
constant uncertainty and anxiety is also referred to. This suggests that
the transformation implied does not mean guaranteed future involve-
ment in clinical trials without worries about risks. To appropriate
Dennis’s (2017) conception of transformation, who states the concept
often invokes a sense of fixed stability. However, stabilising should not
be seen to refer to coming to a fixed state, but indicates how these
experiences are continuous part of formation and play a significant role
in preparations and feelings about future drug use.
Healthy volunteers transforming into ‘seasoned’ volunteers may not
entail a stable process, rather it is a continuous process in which
questions about whether to trust professionals, institutional processes
and one's worth arise in different ways. Significantly, alienation feeds
participants' mistrust in the process: ‘ … it's not that you [stop] finding it
unsettling it's just that you find ways of coping with the challenges I guess. I
often focus on the reward at the end … so it's not like I am completely used
[to doing it] … ’ Contingency of trust and role of affect is illustrated in
the uncertainty around the effect of the drug. Despite challenging and
unsettling experiences, some continue participating repeatedly. Of
significance, healthy volunteer's coping strategies are also embedded in
lived experiences of the clinical trial itself, which I now turn to.
8. Experiential knowledge as a way of building trust
The basis of participants' continued involvement and trust seems
strongly dependent on positive or negative experiences. For most,
taking part in a trial free of adverse drug effects motivated them to
return. This common theme is well articulated here: ‘ … I have done
these (clinical trials) for a long time now and have never had any (un-
expected side effects) so I guess it makes you feel more comfortable I guess…
’
Such positive experiences become the basis on which future deci-
sions made. A clinical drug trial without any adverse drug reactions,
meant the likelihood of repeat participation: ‘ … certain factors de-
termine your involvement, you know. Your past experience if all went well,
and staff were nice …, and how good the facilities [are]’ (Todd). However,
note how reference to staff being nice sits in contradiction to claims that
the process is fraught with surveillance and restrictions. For some
participants, experiences were not just about having a trial free of ad-
verse effects but about relations with the staff and the quality of facil-
ities. Power relations come into play as being treated well by staff was
often seen as the sign of professional expertise and worth referencing
when considering further participation. As Zoltan puts it: ‘they always
treat me nice and kind, they sometimes call me to find out how I am or to
invite me to another trial … ’ Here trust does not just develop from
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information packs and media reports but reflects the experience of
being treated as a valuable part of the clinical trial process. For these
participants, positive experiences meant that risks were seen as normal
in a ‘usual or everyday sense’ (Peretti-Watel, 2014):
‘ … there are risks, but so is life in general, one has to do what they
have to do in life to make ends meet, you know, so it doesn't worry
me at all. Yes, I do think about “what ifs” [what if a trial goes
wrong] but I do that in most things in my life’ (Wallace)
Touchwood nothing bad has happened to me so far. So (I go into the
trial) believing that nothing bad will ever happen to you. You will
always be fine … and you do see things (risks) as normal (Neil)
Perceived positive experiences become bases on which future in-
volvement and perceptions of safety are established. In terms of ‘be-
coming-with’, involvement is a complicated process as individuals
begin to include their bodily experiences or lack of it as evidence of
safety. Some participants start to escalate their involvement by taking
part in trials they previously avoided.
‘ … before I got on to the first trial I did some research … but for the
second one… I did not even bother. The third again I didn't bother. I
thought it was going to be fine … ’ (James).
James' account was shared among participants; most talked of
adopting a cautious approach by conducting personal research on the
trial drugs but escalated involvement and lowered their guard the more
trials they participated in without adverse effects. This is captured in
Neil's reflection on why he did not do any further research on sub-
sequent drug trials:
You start to think, because the people doing it [conducting the
clinical trial] are professionals, and then you know they can be trusted,
you know, to do their job right … then I am more likely to do it again
and worry less. I trust that they know what needs to be done (Neil).
Notably, this ‘lowering of their guard’ occurs in a context where
professionals claim the clinical trials are safe. At this point for volun-
teers, risk becomes absent. There is temporary loss of mistrust in that
they begin to take these positive ‘uneventful’ experiences as markers of
safety as well as future reference points of what constitutes risky trials.
Predictably, they start to see professionals and institutions as vested in
their well-being and thus worth trusting.
I trust that they would be honest… and give me the support I need. I
don't think they would lie, otherwise, it will damage their image and
reputation (John).
I have some trust in these people, in the institutions doing their
studies. When you are on the trial, you only have one option but
trust they are your friends at that particular moment. So, you have
to trust them (Neil).
Between them, John and Neil had taken part in 15 clinical trials and
at the time of the interview had expressed interest in further clinical
trial participation. Pertinent here is how their views are not based on
consent or information; they trust assuming that their safety guarantees
good professional practice. Not a simple relationship between two
parties, this should be seen in the context of the broader assemblage of
trust, including governance processes, social relations and circum-
stances.
However, for some, negative experiences drew them to question the
process, affecting perceptions of the professionals' expertise and abil-
ities:
‘Immediately after that [experiencing unexpected side effects], I was
thinking I cannot trust the researchers they don't know what they
are doing’ (John)
[After experiencing unexpected side effects]. It makes me lose
confidence in the trial maker's ability to know everything about the
drug and its effects, and I do not trust them fully after this. I am
becoming cynical. There is a limit to what they can know or predict
and that makes me more hesitant (Wallace)
It is important to note that John earlier talked about trusting re-
searchers and the process as unavoidable, however, experiencing un-
expected side effects led him to question the researchers' abilities. He
still continued participating in clinical trials with his doubts none-
theless. After this experience, Wallace stopped taking part in what he
considered “risky” phase trials, opting instead to participate in the
perceived “less risky” flu vaccine trials. Note how this change in per-
ception is predicated on bodily experiences of trial drug side effects.
Such experiences may not result in complete loss of trust in institutions
or clinical drug trial process but a more cautious approach. This high-
lights temporality and fluidity (Rhodes et al., 2016) of trust as an as-
semblage. For some, experiencing severe expected or unexpected ad-
verse effects led to broader questions about safety and underlined the
reality of risks:
I have had some experiences like three or four times, where some of
us were told to go back home because someone [healthy volunteer]
had some unexpected side effect to the drugs. Some of those were
quite serious but obviously, we were not told the extent or how
serious. So, kind of lucky it wasn't me really but it's common (Jake).
What we experienced was unexpected and out of this world. It was
akin to being on LSD [or] marijuana. It was noticeable in such things
as hallucinations and loss of track of time, lying in bed for five
hours. And you are not aware of it, giggling and laughing … but
yeah, it was crazy and scary and worried … because it wasn't in-
cluded in the list … but I have done a couple more after that (Jules).
Note in Jake's account reference to ‘three or four times' and Jules' ‘I
have done a couple after that’, indicating that experiencing adverse
effects did not discourage participation. For other participants, un/ex-
pected adverse effects were explained away as bad luck or the sig-
nificance of the problem was underplayed:
I was very lucky. I only developed a blood clot on the last day and it
was only a 12 cm one, which within 24 hours was down to 3 cm. I
was, lucky I did panic a bit but at the same time, I was, like, it was
the last day of dosing … I know some had, like, five or six blood
clots, and big, but the clots were on the sites of the cannula
stretching upwards, and everyone was panicking, saying if it moves
to your heart or brain, you may have a stroke or something like that.
It was scary, you know, and maybe I am putting it mildly when I say
I panicked a little. (Kristof).
The presence or lack of unexpected adverse effects on bodies be-
come the basis on which healthy volunteers start to trust or question
safety in clinical trials, illustrating how repeat volunteering is not a
single bounded event but a process evolving with time - participants
vacillating between trust and mistrust. Becoming a repeat healthy vo-
lunteer does not necessarily entail a fixed state of understanding or
perceiving risks as normal or acceptable. Rather it is a state of constant
flux where negotiating trust and mistrust is constant.
9. Discussion and conclusion
This research provides an understanding of trust among repeat
healthy volunteers. It contributes to sociological research by Abadie
(2010); Elliott (2008) and Fisher (2015) among others, who have over
the years illustrated how repeat volunteering occurs among disen-
franchised populations in the US. This research extends this notion, by
demonstrating the role of trust among healthy volunteers in the UK,
who are employed, yet engage in the risky business of healthy vo-
lunteering to make ends meet. The paper demonstrates how healthy
volunteers rationalise repeat participation in clinical drug trials.
Moving away from a sole focus on rationality, this paper has at-
tempted to move us to consider trust as entailing a process involving
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decision-making located in wider social networks and relations. As
Corrigan (2003) argued, informed consent is a social - not just objective
- process. From the participants accounts trust is illustrated as con-
stituting an uncertain, fragile and unpredictable contingency. Socio-
logical work demonstrates a need to rethink fixed processes of consent
and recruitment as they limit understanding of the processes that lead
to trust and repeat volunteering. This stance suggests taking a ‘careful’
approach (Puig de la Bellacasa, 2011; Dennis, 2017), aware that the
world around shapes people's views and experiences in clinical drug
trials and consequently for some brings about trust, mistrust and repeat
volunteering. One limitation of current approaches to maintaining trust
and trial recruitment from a CRO perspective, has been over-empha-
sising structural interventions and policies to improve practices
(Hudson et al., 2016) such as the informed consent process (Corrigan,
2003) with little attention on how individuals experience and negotiate
involvement in clinical drug trials and how they come to trust or mis-
trust in these processes. Dennis (2017) and Ahmed (2004) highlight
contingency, in a classic Latin meaning of (Latin: contingere: com-, with;
tangere, to touch) linked to proximity, to get close enough to touch another
and to be moved by another (Ahmed, 2004, p. 28). Dennis (2017) de-
velops this by calling for an existential awareness of how individual
affect inside relates to the social world outside. In terms of healthy
volunteer experiences, I suggest an awareness of relations involved in
the clinical trial process between self and others, including the mate-
riality of the drugs themselves and their role. Trust should not be seen
as an isolated act of rational actors; rather rationality itself is embedded
in a complex assemblage of relations between participants, feelings,
experiences with the drugs and other actors in this process. This as-
semblage acts as a basis for knowledge brought to decision-making
processes and claims to trust/mistrust in the clinical drug trial process.
While a focus on the ideal capable individual with human liberties
as the universal moral principle for guiding discussions in clinical drug
trials is useful, there is need to consider the ‘effect of different pro-
grammes and campaigns on individuals’ capacity for freedom and ethical
self-formation’ (Keane, 2003, p. 231; p. 231). This means reconsidering
human involvement in clinical trials beyond objective facts and risk
assessments made by rational informed actors as a ‘matter of concern’
(Latour, 2004) whereby what constitutes trusting action becomes open
to critical consideration by rethinking trust as an assemblage involving
socio-economic circumstances, bodily experiences and sensations of
adverse effects and relations. Consequently, the process is less about
facts than ‘becoming-with’ (Deleuze, 2004; Dennis, 2017) wherein
analysis of trust and mistrust takes into account that seemingly in-
dividual acts occur in complex relational, processual, uncertain and
unstable ‘events’. Trust in repeat volunteering is not a bounded event
but shaped by broader networks, including ‘what gets made in research
and practice alike, and the bodily boundaries we inevitably bring into being’
(Dennis, 2017, p.14; p.14). This necessitates further sociological dis-
cussions about trust to include broader issues on how trust is estab-
lished in the interactions within and outside the clinical trial processes
as participants ‘become-with’ repeat healthy volunteering.
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